HMGB3 and invasive breast carcinoma: HMGB3 was found to be overexpressed in a variety of cancers, including breast invasive carcinoma, sarcoma, skin cutaneous melanoma, ovarian serous cystadenocarcinoma, and acute myeloid leukemia (53, 54).